COMMUNIQUÉS West-GlobeNewswire

Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia

12/12/2017 - 00:00

CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT ), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome editing [...]

GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs Raising Gross Proceeds of $317.4 Million and Full Exercise of Underwriter’s Option to Purchase Additional ADSs

11/12/2017 - 23:19

LONDON, Dec. 11, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its [...]

Enzymotec Shareholders Approve Proposed Acquisition by Frutarom

11/12/2017 - 23:15

MIGDAL HA’EMEQ, Israel, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ: ENZY ) (“Enzymotec” or the “Company”), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and nutritional [...]

Scythian Biosciences Corp. Announces Appointment of Ottis Anderson to Pro Athlete Advisory Committee

11/12/2017 - 23:07

TORONTO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the " Company " or “ Scythian ”) (TSXV:SCYB) (Frankfurt: 9SB ) (OTC Pink:SCCYF) is pleased to announce that it has appointed Ottis Jerome “O.J.” [...]

Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study

11/12/2017 - 22:46

PHILADELPHIA and OXFORD, United Kingdom, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, submitted updated data from its completed pilot study [...]

Karmanos Cancer Institute’s 24th Annual Partners Night continues to drive the future of cancer research

11/12/2017 - 22:34

DETROIT, Dec. 11, 2017 (GLOBE NEWSWIRE) -- When dedicated community members, including those touched by cancer, come together to support cancer research at Karmanos, it’s another way of describing the Barbara Ann [...]

Mustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical Trial

11/12/2017 - 22:30

Trial investigators at City of Hope announce first-reported complete response from a CAR T therapy in a BPDCN patient, additional complete response achieved in AML Investigators found infusions of MB-102 are safe and [...]

Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting

11/12/2017 - 22:30

Preclinical data show dual inhibition of MDM2 and MDMX restores p53 function Data demonstrate strong anti-cancer effects in models of T-cell lymphomas and acute myeloid leukemia ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE [...]

Fortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society of Hematology Annual Meeting

11/12/2017 - 22:30

Columbia University reports Caelum Biosciences’ CAEL-101 was well tolerated, demonstrated early and clinically efficacious organ response in Phase 1a/1b trial in AL amyloidosis City of Hope announces Mustang Bio’s MB- [...]

Minerva Neurosciences Names Richard Russell President

11/12/2017 - 22:30

WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV ), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) [...]

Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428, PTI-801 and PTI-808 in Healthy Volunteers and Patients with Cystic Fibrosis

11/12/2017 - 22:21

CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI ), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to [...]

AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017

11/12/2017 - 22:20

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC ), a biotechnology company conducting human clinical trials of adeno-associated virus ( [...]

Avinger Announces Change in Board Leadership

11/12/2017 - 22:15

REDWOOD CITY, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ: AVGR ) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that [...]

Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M

11/12/2017 - 22:15

Analysis of patient data from a large U.S. library revealed that twenty-five percent of Multiple Myeloma patients have CD33 expression on their multiple myeloma cells supporting the rational for targeting this antigen [...]

Wright Medical Group N.V. to Present at 36th Annual J.P. Morgan Healthcare Conference

11/12/2017 - 22:15

AMSTERDAM, The Netherlands, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ: WMGI ) announced today that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, [...]

argenx announces launch of proposed public offering in the United States

11/12/2017 - 22:11

Regulated information - Inside information December 11, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of [...]

Data from Phase 1 Studies of Ivosidenib or Enasidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation

11/12/2017 - 22:05

- Ivosidenib and Enasidenib Evaluated in Combination with Standard Induction (7+3) Chemotherapy or Azacitadine in Newly Diagnosed Patients From Two Phase 1 Studies - - Phase 3 Trial of Ivosidenib or Enasidenib Combined [...]

Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent Developments

11/12/2017 - 22:05

-- Avid Bioservices Records Revenues of $12.8 Million in the Second Quarter of FY2018 -- -- Transition to a Dedicated CDMO Business Nearing Completion -- TUSTIN, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Peregrine [...]

Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer

11/12/2017 - 22:05

BURLINGTON, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced that Scott Kelley, M.D., has been named Chief Medical Officer. Dr. Kelley previously served as the company’ [...]